Developing a new HIV vaccine using advanced technology
Official title: The Multi-omics Vaccine Evaluation (MOVE) Consortium
Funded at Scripps Research Institute, the · NIH-11076767 · Data updated 2026-11-12
This study is working on a new HIV vaccine that aims to help your body build strong defenses against the virus, so you can have better protection against AIDS.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | June 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,796,659 |
| NIH project number | 5P01AI177683-03 |
| Project ID | NIH-11076767 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at high risk for HIV infection or those living with HIV who are seeking new treatment options.
✕Less likely to help
Patients who are not at risk for HIV or those who are already effectively managing their HIV with existing treatments may not receive benefit from this research.
What this research studies
This research focuses on creating an effective HIV vaccine that can induce broadly neutralizing antibodies (bnAbs) to combat the AIDS pandemic. The approach involves using a series of immunogens delivered in a specific sequence to ensure the immune system can respond effectively without allowing the virus to escape. By integrating multi-omics technology, the research aims to enhance the speed and precision of vaccine development, allowing for a more comprehensive evaluation of the immunogens used. Patients may benefit from this innovative approach as it seeks to provide long-lasting immunity against HIV.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking HIV vaccine that offers durable protection against the virus.
How similar studies have gone: Other research has shown promise in using multi-omics approaches for vaccine development, suggesting potential success for this innovative strategy.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Briney, Bryan — Scripps Research Institute, the
- Study coordinator: Briney, Bryan
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.